Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORAGER-2
CTR20254432Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vepugratinib in transitional cell carcinoma (TCC), sponsored by Eli Lilly and Company. Started Dec 2025; status: active.
02
Drugs
vepugratinib
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20254432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254432.